Literature DB >> 33708204

Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis.

Yujing Fan1, Yunpeng Li1, Yanjie Chu1, Jing Liu1, Lin Cui1, Dekai Zhang2.   

Abstract

Liver cirrhosis is one major cause of mortality in the clinic, and treatment of this disease is an arduous task. The scenario will be even getting worse with increasing alcohol consumption and obesity in the current lifestyle. To date, we have no medicines to cure cirrhosis. Although many etiologies are associated with cirrhosis, abnormal intestinal microbe flora (termed dysbiosis) is a common feature in cirrhosis regardless of the causes. Toll-like receptors (TLRs), one evolutional conserved family of pattern recognition receptors in the innate immune systems, play a central role in maintaining the homeostasis of intestinal microbiota and inducing immune responses by recognizing both commensal and pathogenic microbes. Remarkably, recent studies found that correction of intestinal flora imbalance could change the progress of liver cirrhosis. Therefore, correction of intestinal dysbiosis and targeting TLRs can provide novel and promising strategies in the treatment of liver cirrhosis. Here we summarize the recent advances in the related topics. Investigating the relationship among innate immunity TLRs, intestinal flora disorders, and liver cirrhosis and exploring the underlying regulatory mechanisms will assuredly have a bright future for both basic and clinical research.
Copyright © 2021 Fan, Li, Chu, Liu, Cui and Zhang.

Entities:  

Keywords:  bacterial translocation; dysbiosis; gut-liver axis; liver cirrhosis; toll-like receptors

Mesh:

Substances:

Year:  2021        PMID: 33708204      PMCID: PMC7940369          DOI: 10.3389/fimmu.2021.608498

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  82 in total

1.  The normal flora may contribute to the quantitative preponderance of myeloid cells under physiological conditions.

Authors:  Shi Liang; Hu LiHua
Journal:  Med Hypotheses       Date:  2011-01       Impact factor: 1.538

Review 2.  The Human Gut Microbiome in Liver Diseases.

Authors:  Brian C Davis; Jasmohan S Bajaj
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

Review 3.  Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome.

Authors:  Amandeep Singh; Gail A Cresci; Donald F Kirby
Journal:  Nutr Clin Pract       Date:  2018-08-02       Impact factor: 3.080

4.  Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis.

Authors:  Isabel Gómez-Hurtado; Paula Gimenez; Irma García; Pedro Zapater; Rubén Francés; José M González-Navajas; Chaysavanh Manichanh; José M Ramos; Pablo Bellot; Francisco Guarner; José Such
Journal:  Liver Int       Date:  2017-09-13       Impact factor: 5.828

5.  Protective effects of phenolics rich extract of ginger against Aflatoxin B1-induced oxidative stress and hepatotoxicity.

Authors:  Vipin A V; Raksha Rao K; Nawneet Kumar Kurrey; Anu Appaiah K A; Venkateswaran G
Journal:  Biomed Pharmacother       Date:  2017-05-02       Impact factor: 6.529

6.  Pectin Alleviates High Fat (Lard) Diet-Induced Nonalcoholic Fatty Liver Disease in Mice: Possible Role of Short-Chain Fatty Acids and Gut Microbiota Regulated by Pectin.

Authors:  Wenfeng Li; Kun Zhang; Hongyan Yang
Journal:  J Agric Food Chem       Date:  2018-07-20       Impact factor: 5.279

Review 7.  Gut microbiome and nonalcoholic fatty liver diseases.

Authors:  Lixin Zhu; Robert D Baker; Susan S Baker
Journal:  Pediatr Res       Date:  2014-10-13       Impact factor: 3.756

8.  Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites.

Authors:  G Garcia-Tsao; F Y Lee; G E Barden; R Cartun; A B West
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

9.  Targeting gut flora to prevent progression of hepatocellular carcinoma.

Authors:  Marion Darnaud; Jamila Faivre; Nicolas Moniaux
Journal:  J Hepatol       Date:  2012-08-30       Impact factor: 25.083

10.  Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

Authors:  Agustín Albillos; Antonio de la Hera; Mónica González; Jose-Luis Moya; Jose-Luis Calleja; Jorge Monserrat; Luis Ruiz-del-Arbol; Melchor Alvarez-Mon
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  3 in total

Review 1.  The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective.

Authors:  Li Wang; Zheng-Min Cao; Li-Li Zhang; Juan-Mei Li; Wen-Liang Lv
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

2.  Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis.

Authors:  Haonan Zhang; Jian Gao
Journal:  PLoS One       Date:  2022-08-30       Impact factor: 3.752

Review 3.  Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Authors:  Roberta Forlano; Mathuri Sivakumar; Benjamin H Mullish; Pinelopi Manousou
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.